KD

Kalyani Devi Thummalacherla

Active Director Director DIN 10966864
DIN 10966864 First appointment Feb 2025 Primary industry Paper
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Feb 2025
Shareholding value β€’β€’β€’β€’ Premium profile

About Kalyani Devi Thummalacherla

Data last updated:

Kalyani Devi Thummalacherla is a Director at Anlisa Biotech Private Limited (since 2025). The company operates in Paper.

DIN 10966864
Primary Designation Director
Industry Paper
First Appointment 24 Feb 2025
Oldest Company Age 1 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Anlisa Biotech Private Limited U21001TS2025PTC194495
Director24 Feb 20252025Active

Board colleagues of Kalyani Devi Thummalacherla

NameDINCompanyDesignation
Balendu Sankara Prasad Avvaru10966863Anlisa Biotech Private LimitedDirector

Directorship timeline

Open interactive timeline →
Anlisa Biotech Private Limited
Premium access

Shareholding and investment profile for Kalyani Devi Thummalacherla

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Kalyani Devi Thummalacherla

Kalyani Devi Thummalacherla currently holds 1 directorship: Anlisa Biotech Private Limited (Director, since 24 Feb 2025).

Kalyani Devi Thummalacherla was first appointed on 24 Feb 2025 as Director at Anlisa Biotech Private Limited.

The current boards of Kalyani Devi Thummalacherla's companies include Balendu Sankara Prasad Avvaru (Anlisa Biotech Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available